Cart
sales@molnova.com
Ibalizumab
CAS No. 680188-33-4
Ibalizumab( —— )
Catalog No. M36665 CAS No. 680188-33-4
Ibalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 1198 | Get Quote |
|
| 5MG | 1881 | Get Quote |
|
| 10MG | 2537 | Get Quote |
|
| 25MG | 3643 | Get Quote |
|
| 50MG | 4922 | Get Quote |
|
| 100MG | 6498 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIbalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionIbalizumab(TMB-355) is a humanized IgG4 monoclonal antibody that acts as a CD4 receptor inhibitor, blocking the entry of HIV-1 into cells by binding to the CD4 receptor.
-
DescriptionIbalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV Protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number680188-33-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785. ?
molnova catalog
related products
-
Bevirimat
Bevirimat(PA-457) is a first-in-class inhibitor of HIV-1 maturation blocking the cleavage of the Gag capsid (CA) precursor CA-SPI to mature CA protein during virion maturation.
-
CHLOROQUINE
Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis.
-
I-XW-053
I-XW-053 is an inhibitor of capsid targeted HIV-1 replication using the hybrid structure based method to block the interface between CA N-terminal domains (NTD-NTD interface) with micromolar affinity.
